Non-Viral
Approaches
Multiple modalities to treat neurological diseases.
Monoclonal Antibodies
The Voyager team has discovered multiple antibodies as part of the anti-tau antibody program and other research programs. Some of these antibodies are being advanced in their native form, while others are being advanced by applying our gene therapy or Voyager NeuroShuttle™ technologies.
VYGR-NeuroShuttle: Next-Gen Approach to Neurotherapeutics
Voyager NeuroShuttle™ (VYGR-NeuroShuttle) is a non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier (BBB).
Platform optimization and program development across therapeutic modalities ongoing, in rodents and non-human primates.
How It Works:
Multiple potential opportunities for Voyager’s NeuroShuttle platform to create value:
- Increase efficacy by increasing on-target delivery
- Improve safety by reducing peripheral exposure
- Lower COGS by reducing dose needed
- Expand opportunity for shuttles: ALPL first of multiple receptors identified